Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas rheumatoid arthritis (RA) Registry
Main finding · Proportions achieving CDAI LDA, remission and MCID in CDAI (unadjusted); adjusted effectivenessResult — go to the resultOR for achieving MCID in CDAI 0.65 95% CI 0.43–0.98Authors' conclusion
This analysis of real-world data from the CorEvitas RA Registry did not show differences in clinical effectiveness and treatment persistence rates in b/tsDMARD-naïve patients initiating ETN, ADA, or JAKi as first-line targeted therapy either alone or in combination with csDMARDs.
Study context
- Population
- b/tsDMARD-naïve adults (≥ 18 years) with RA in the CorEvitas RA Registry initiating ETN, ADA or a JAKi, November 2012–June 2021, with 6 and/or 12 months' follow-up803 ETN, 984 ADA, 361 JAKi with 6-month follow-up
- Participants
- 1,059 / 1,327 / 581
- Exposure
- ETN vs ADA vs JAKi as first-line targeted therapy, alone or with csDMARDs
- ETNn = 1,059reference
- ADAn = 1,327
- JAKin = 581
- Outcome
- Treatment persistence and effectiveness outcomes, incl. change in CDAI and PROs
- Follow-up
- 6 and 12 months
Methodological detailsreal-world, covariate-adjusted linear and logistic regression, exploratory monotherapy analysis
- Real-world
- Covariate-adjusted linear and logistic regression
- Exploratory monotherapy analysis
Main finding
As reported in the abstract
Proportions achieving CDAI LDA, remission and MCID in CDAI (unadjusted); adjusted effectiveness · 6 months
OR for achieving MCID in Clinical Disease Activity Index (CDAI)
0.65
95% CI 0.43–0.98
By group
JAKivs ETN
OR for achieving MCID in CDAI 0.65 (95% CI 0.43–0.98)
Observational data: associations, not effects.
Further findings
Treatment persistence (remained on therapy) · 6 months
Effectiveness outcomes at 12 months and among monotherapy initiators
- No differences in effectiveness outcomes between the groups
- Sensitivity analysis among monotherapy initiators
Original publication
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis Res Ther. Published 9 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →